Next Article in Journal
Development of an In Vitro Test Method to Replace an Animal-Based Potency Test for Pertactin Antigen in Multivalent Vaccines
Previous Article in Journal
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome
Previous Article in Special Issue
Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 2
10.3390/vaccines11020274
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Vaccines against Group B Coxsackieviruses and Their Importance

by
Kiruthiga Mone
1,†,
Ninaad Lasrado
1,2,†,
Meghna Sur
1 and
Jay Reddy
1,*
1
School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
2
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2023, 11(2), 274; https://doi.org/10.3390/vaccines11020274
Submission received: 1 January 2023 / Revised: 23 January 2023 / Accepted: 25 January 2023 / Published: 27 January 2023
(This article belongs to the Special Issue The Immune Response to Viral Infection)
Browse Figures
Versions Notes

Abstract

The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4 could accelerate the development of type 1 diabetes (T1D). Yet, no vaccines against these viruses are currently available. In this review, we have analyzed the attributes of experimentally tested vaccines and discussed their merits and demerits or limitations, as well as their impact in preventing infections, most importantly myocarditis and T1D.
Keywords: vaccine; coxsackieviruses; viral myocarditis; type 1 diabetes; viral insulitis vaccine; coxsackieviruses; viral myocarditis; type 1 diabetes; viral insulitis

Share and Cite

MDPI and ACS Style

Mone, K.; Lasrado, N.; Sur, M.; Reddy, J. Vaccines against Group B Coxsackieviruses and Their Importance. Vaccines 2023, 11, 274. https://doi.org/10.3390/vaccines11020274

AMA Style

Mone K, Lasrado N, Sur M, Reddy J. Vaccines against Group B Coxsackieviruses and Their Importance. Vaccines. 2023; 11(2):274. https://doi.org/10.3390/vaccines11020274

Chicago/Turabian Style

Mone, Kiruthiga, Ninaad Lasrado, Meghna Sur, and Jay Reddy. 2023. "Vaccines against Group B Coxsackieviruses and Their Importance" Vaccines 11, no. 2: 274. https://doi.org/10.3390/vaccines11020274

APA Style

Mone, K., Lasrado, N., Sur, M., & Reddy, J. (2023). Vaccines against Group B Coxsackieviruses and Their Importance. Vaccines, 11(2), 274. https://doi.org/10.3390/vaccines11020274

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop